Does Molina Healthcare Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, two cytokines central to type 2 inflammatory disease. The FDA first approved it in March 2017 for moderate-to-severe atopic dermatitis in adults, and the label has since expanded to cover adolescents aged 12 and older, children aged 6 months and older, and multiple additional indications. [1]

FDA-Approved Indications

As of mid-2024, Dupixent carries FDA approval for six distinct indications:

• Moderate-to-severe atopic dermatitis (adults and pediatric patients down to 6 months)
• Moderate-to-severe asthma with an eosinophilic phenotype or oral-corticosteroid-dependent asthma
• Chronic rhinosinusitis with nasal polyps (CRSwNP)
• Eosinophilic esophagitis (EoE) in patients aged 12 and older
• Prurigo nodularis in adults
• Moderate-to-severe COPD with type 2 inflammation (approved June 2024)

Each approved indication has its own set of clinical criteria that insurers, including Molina, use to evaluate prior authorization requests. [2]

Why Price Makes Coverage Critical

The manufacturer's wholesale acquisition cost runs approximately $3,700 per month, or roughly $44,000 per year. Without insurance approval or manufacturer assistance, most patients cannot sustain therapy. A 2022 analysis in the Journal of the American Academy of Dermatology found that biologic non-adherence due to cost directly correlated with disease relapse in atopic dermatitis, underscoring why securing coverage is a clinical priority, not just a billing formality. [3]

How Molina Healthcare Works: Medicaid Managed Care vs. Marketplace Plans

Molina Healthcare operates primarily as a Medicaid managed care organization. It contracts with state Medicaid agencies in roughly 20 states to administer benefits for Medicaid and CHIP beneficiaries. In some states it also offers Qualified Health Plans (QHPs) through the ACA Marketplace and, to a lesser extent, Medicare Advantage plans.

Medicaid Managed Care Members

For members enrolled through a state Medicaid contract, coverage rules are shaped by two layers: the federal Medicaid statute and the state-specific contract Molina signs with the state Medicaid agency. Federal law requires Medicaid to cover prescribed drugs that appear on a state's preferred drug list (PDL) or that a physician has documented are medically necessary. Dupixent appears on the PDL of most states as a non-preferred specialty drug, meaning it requires prior authorization before dispensing. [4]

ACA Marketplace (QHP) Members

QHP members face a separate formulary. Molina's Exchange plans typically place Dupixent in Tier 4 or Tier 5 (specialty biologic tier), with prior authorization and, in many states, a step-therapy requirement. Because these plans are subject to the ACA's essential health benefits framework, a plan cannot categorically exclude a medically necessary biologic once step therapy is satisfied.

Key Difference

Medicaid members have stronger federal protections against arbitrary denials (42 CFR § 438.210 governs managed care coverage decisions), while QHP members can appeal under ACA external review rules. Both pathways ultimately provide a route to coverage if the clinical documentation is solid.

Prior Authorization Requirements for Dupixent Through Molina

Prior authorization (PA) is required for Dupixent across all Molina plan types. The PA process is where most access barriers emerge, and understanding the exact criteria gives prescribers the best chance of approval on the first submission.

Standard Clinical Criteria (Atopic Dermatitis)

Molina's PA criteria for Dupixent in atopic dermatitis generally require all of the following:

• A confirmed diagnosis of moderate-to-severe atopic dermatitis, often documented with an Investigator's Global Assessment (IGA) score of 3 or 4 or an Eczema Area and Severity Index (EASI) score above 16
• Age eligibility per FDA label for the requested dose
• Documentation of an adequate trial and failure of at least one medium-to-high-potency topical corticosteroid or calcineurin inhibitor lasting a minimum of 4 to 8 weeks
• A prescription from a board-certified dermatologist or allergist/immunologist in many state contracts
• Confirmation that the member does not have active tuberculosis or another contraindicated condition

The key SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that 37-38% of patients on dupilumab 300 mg every two weeks achieved an IGA score of 0 or 1 at 16 weeks, versus 8-10% on placebo (P<0.001), which is the clinical evidence base insurers reference when setting these thresholds. [5]

PA Criteria for Other Indications

For asthma, Molina typically requires a documented eosinophil count of 300 cells/mcL or higher, or documented oral-corticosteroid dependence, plus failure of an inhaled corticosteroid plus one additional controller agent. The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab reduced annualized severe exacerbations by 47.7% in the high-eosinophil subgroup (P<0.001). [6]

For CRSwNP, PA usually requires endoscopic confirmation of bilateral polyps and failure of intranasal corticosteroids for at least 8 weeks.

Submission Tips

Submitting a detailed chart note, relevant scoring tools (IGA, EASI, SNOT-22 for nasal polyps), and a letter of medical necessity on the same day as the PA request reduces back-and-forth by approximately 30-40% based on specialty pharmacy data. Attach all prior treatment records at first submission.

Step Therapy: What You Must Try First

Step therapy (also called "fail first") requires a member to try and fail a lower-cost treatment before the insurer authorizes the preferred drug. For Dupixent, Molina's step therapy protocols vary by indication and state but follow a recognizable pattern.

Atopic Dermatitis Step Therapy

Most Molina contracts require documented failure of:

1. A medium-to-high-potency topical corticosteroid (e.g., triamcinolone 0.1% or clobetasol 0.05%) used for at least 4 weeks
2. A topical calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%) in at least one course

Some states additionally require a trial of crisaborole (Eucrisa) or phototherapy before Dupixent is authorized for adults.

Asthma Step Therapy

For moderate-to-severe asthma, standard step therapy requires an adequate trial of an inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA) at appropriate doses per GINA 2023 guidelines before a biologic is considered. [7]

Step Therapy Override Laws

As of 2024, at least 30 states have enacted step therapy override (STO) laws that require insurers to grant exceptions when a patient has already tried and failed the required drugs, when step therapy poses a clinical risk, or when a patient is stable on a current regimen. If you live in one of these states and Molina's step therapy requirement conflicts with your physician's clinical judgment, a formal override request is a protected right, not a courtesy.

What Happens When Molina Denies Dupixent

Denial of a Dupixent PA is not the end of the road. Molina must follow both federal and state-mandated appeals processes.

Level 1: Internal Appeal (Grievance/Reconsideration)

Submit a written appeal within 60 days of the denial notice. Include:

• A letter of medical necessity from the treating physician
• Peer-reviewed literature supporting use (the SOLO trials, LIBERTY ASTHMA QUEST, or indication-specific data)
• Any additional clinical documentation not included in the original submission

Molina must respond to standard appeals within 30 days and expedited appeals (for urgent clinical need) within 72 hours under 42 CFR § 438.408.

Level 2: External Independent Review

If the internal appeal is denied, members have the right to request an external independent medical review (IMR) through the state insurance commissioner's office. External reviewers overturn biologic denials at a meaningful rate. A 2021 JAMA Internal Medicine analysis of external appeal outcomes found that consumers won approximately 39% of external reviews of drug coverage denials, with biologics overturned at higher rates when peer-reviewed evidence was included. [8]

State Medicaid Fair Hearing

Medicaid members have an additional option: a state fair hearing before an administrative law judge. This process is slower but carries legal weight and is particularly useful when Molina's denial conflicts with state Medicaid PDL policy or a mandated step-therapy exception.

Dupixent Cost Assistance Programs When Coverage Is Denied or Insufficient

Even after a denial, or while an appeal is pending, patients may access Dupixent through manufacturer programs.

Sanofi/Regeneron DUPIXENT MyWay Patient Assistance Program

The DUPIXENT MyWay Patient Assistance Program (PAP) provides free medication to eligible uninsured or underinsured patients. Income eligibility extends to 600% of the federal poverty level, which in 2024 covers a household of four with income up to approximately $180,000. Applications are submitted through the prescribing provider's office or directly at dupixentmyway.com. [9]

CopayAssist Card (Commercially Insured Patients)

For patients with commercial insurance (including Molina's ACA Marketplace QHPs), the Dupixent CopayAssist card reduces patient out-of-pocket cost to $0 per month for eligible patients, with a program maximum of $13,000 per calendar year. Medicaid beneficiaries are not eligible for copay cards under federal anti-kickback rules, so Medicaid members must rely on the PAP or Molina's own cost-sharing protections.

Specialty Pharmacy Bridge Programs

Specialty pharmacies such as Accredo and CVS Specialty that dispense Dupixent also operate bridge programs that provide a 30-day supply at no charge while a PA or appeal is pending. Ask the prescribing office to initiate a bridge request on the day of the initial PA submission.

How to Get Dupixent Approved Through Molina: A Step-by-Step Framework

The following framework consolidates the clinical and administrative steps that give Molina members the highest probability of first-pass PA approval and, if needed, a successful appeal.

Step 1: Confirm Diagnosis and Score Severity

Document the diagnosis with validated scoring tools at the office visit. For atopic dermatitis, record the IGA and EASI scores in the chart note. For asthma, document absolute eosinophil count, baseline FEV1 percent predicted, and annualized exacerbation rate over the prior 12 months.

Step 2: Run and Document Step Therapy

Prescribe the required first-line agents and document the outcome explicitly. "Patient completed an 8-week course of clobetasol 0.05% twice daily with persistent IGA 3, EASI 22" is far more actionable than a generic notation of "failed topical steroids." Dates, doses, and objective scores matter.

Step 3: Submit a Complete PA Package on Day One

A complete package includes:

• Completed Molina PA form (available on the member or provider portal)
• Office visit note with scoring data
• Medication history confirming step therapy
• Letter of medical necessity citing SOLO 1/SOLO 2 (atopic dermatitis) or LIBERTY ASTHMA QUEST (asthma) [5, 6]
• Prior treatment records if therapy was initiated elsewhere

Step 4: Use the Specialty Pharmacy as an Ally

Accredo and CVS Specialty have dedicated PA support teams that track Molina timelines, follow up on missing documentation, and flag cases for expedited review. Routing the prescription to one of these pharmacies on day one creates a parallel support track.

Step 5: Appeal Immediately if Denied

Do not wait for the patient's next appointment. File the internal appeal the same week as the denial with supplemental literature. Schedule the patient for a bridge program in parallel so therapy is not interrupted.

State-by-State Variation in Molina Dupixent Coverage

Molina operates in approximately 20 states, and Medicaid formulary rules differ meaningfully between them. The table below summarizes representative coverage features as of mid-2024.

| State | Dupixent on PDL | Step Therapy Required | STO Law in Effect | |---|---|---|---| | California | Yes (non-preferred) | Yes (topical agents) | Yes | | Texas | Yes (non-preferred) | Yes | No | | Florida | Yes (non-preferred) | Yes | Yes | | Ohio | Yes (non-preferred) | Yes | Yes | | Washington | Yes (non-preferred) | Yes | Yes | | Michigan | Yes (non-preferred) | Yes | Yes | | New Mexico | Yes (non-preferred) | Yes | No |

Coverage determinations and PDL placement are updated annually. Always verify the current formulary status by calling Molina Member Services at the number on your insurance card or by searching the state Medicaid agency's current PDL online. [10]

Clinical Evidence Supporting Dupixent Coverage Decisions

Insurers reference peer-reviewed trial data when writing PA criteria. Understanding the key trials helps physicians frame their medical necessity letters.

Atopic Dermatitis: SOLO 1 and SOLO 2

The Phase 3 SOLO 1 and SOLO 2 trials enrolled a combined 1,379 adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. At 16 weeks, 37% and 36% of patients on dupilumab 300 mg every two weeks achieved an IGA of 0 or 1 (clear or almost clear), compared with 10% and 8% on placebo respectively (P<0.001 for both). Peak pruritus NRS scores dropped by more than 50% in the dupilumab arms. [5]

Asthma: LIBERTY ASTHMA QUEST

LIBERTY ASTHMA QUEST (N=1,902) evaluated dupilumab 200 mg and 300 mg every two weeks versus placebo in adults with uncontrolled moderate-to-severe asthma. In the pre-specified subgroup with baseline eosinophils of 300 cells/mcL or higher (roughly 60% of the trial population), dupilumab reduced annualized severe exacerbation rates by 47.7% and improved pre-bronchodilator FEV1 by 0.21 L over placebo (P<0.001). [6]

Prurigo Nodularis: PRIME and PRIME2

The PRIME (N=151) and PRIME2 (N=160) trials demonstrated that 58% of dupilumab-treated patients achieved a 4-point or greater reduction in Worst Itch NRS at 24 weeks versus 20% on placebo (P<0.001), the evidence base used by Molina when evaluating prurigo nodularis PAs. [11]

The American Academy of Dermatology's Atopic Dermatitis Clinical Practice Guidelines state: "Dupilumab is recommended for patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy." [12]

The Global Initiative for Asthma (GINA) 2023 report notes: "Anti-IL-4Ralpha (dupilumab) is recommended as add-on therapy for adults with severe uncontrolled Type 2 asthma who are not well-controlled with high-dose ICS-LABA." [7]

Pediatric Coverage: Children and Adolescents on Molina

Dupixent holds FDA approval for atopic dermatitis down to 6 months of age. Molina Medicaid plans covering children through CHIP must cover Dupixent when medically necessary for pediatric members who meet age-appropriate criteria. The Phase 3 LIBERTY AD PEDS trial in children aged 6 to 11 (N=367) showed 30% achieved IGA 0/1 at 16 weeks versus 11% on placebo (P<0.001), providing the evidence base for pediatric PA requests. [13]

Pediatric PA submissions should include growth charts, any documentation of sleep disruption from itch (a marker of disease severity), and school absence records if available. These real-world severity markers can strengthen a medical necessity letter significantly.

Practical Tips for Molina Members

A few direct points that save time:

• Call before prescribing. Contact Molina's pharmacy benefits line (listed on the insurance card) to confirm current PA criteria before the office visit. Criteria change annually.
• Use Molina's provider portal. Electronic PA submissions through the portal receive status updates faster than fax.
• Request peer-to-peer review. If a PA is denied by a Molina pharmacy reviewer, the prescribing physician can request a peer-to-peer call with Molina's medical director within 24-48 hours of denial. This conversation overturns denials at a higher rate than written appeals alone in specialty drug cases.
• Document itch and sleep data. Peak pruritus NRS scores and validated sleep instruments (POEM, DLQI) carry direct weight in PA criteria language. Record them at every visit.
• Re-apply after 12 months. Some denials are based on plan-year criteria that reset annually. A patient who fails step therapy adequately within the current plan year may qualify under next year's updated criteria with a fresh submission.